Emergex closes US$11m Series A round led by Vickers Venture Partners
Add BT as a preferred sourceBIOTECH firm Emergex has raised more than US$11 million in a Series A funding round to develop synthetic vaccines for infectious diseases, it said on Thursday.
The investment round was led by Vickers Venture Partners.
Founded in 2016, Emergex focuses on developing vaccines to prevent diseases such as Zika, dengue fever, Ebola and the pandemic flu.
According to the company, its vaccines are unlike traditional vaccines which use live viruses. Instead, Emergex uses synthetic non-biological components that "programme immune cells to destroy pathogen-producing cells", it said.
In addition, chairman of Vickers Venture Partners Finian Tan will also join Emergex's board as a non-executive director.
Said Dr Tan: "We see great potential in Emergex's technology as it allows vaccines to be produced quickly, administered easily and sold at a fraction of current prices."
Singapore-based Vickers Venture Partners specialises in early-stage investments in Asia. Its portfolio covers the life sciences, technology, media and telecommunications, as well as consumer and financial services.
Share with us your feedback on BT's products and services
TRENDING NOW
How BYD disrupted Singapore’s car market – and why the strategy is turning on itself
Too little, too late? Manila’s billion-dollar bid to ignite its sputtering EV industry
Vietnam seeks US$76 billion a year from capital markets to ease reliance on banks
MSCI drops S-E Asian heavyweights Sembcorp, GoTo and Ayala Land from global benchmarks
